Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

Abstract: Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. This ad hoc analysis examined treatment outcomes with zanubrutinib...

Full description

Saved in:

Bibliographic Details
Main Authors:	Benjamin M. Heyman, Stephen S. Opat, Björn E. Wahlin, Meletios-Athanasios C. Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Jeffrey V. Matous
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Blood Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952924006931
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CNS Vasculitis Associated with Waldenström Macroglobulinemia
by: Tanawan Riangwiwat, et al.
Published: (2016-01-01)

Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia
by: Akshee Batra, et al.
Published: (2020-01-01)

Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom’s Macroglobulinemia
by: Aasems Jacob, et al.
Published: (2017-01-01)

Waldenström Macroglobulinemia and Cerebral Venous Thrombosis: From Diagnosis to Complication
by: Paulo Zoé Costa, et al.
Published: (2019-01-01)

HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom’s Macroglobulinemia
by: Mark R. Wallace
Published: (2020-01-01)

Multimodal Imaging of Waldenstrom Macroglobulinemia-Associated Hyperviscosity-Related Retinopathy Treated with Plasmapheresis
by: Michael J. Schatz, et al.
Published: (2021-01-01)

Waldenstrom’s Macroglobulinemia: A Report of Two Cases, One with Severe Retinopathy and One with Renal Failure
by: Naoko Kudo, et al.
Published: (2017-01-01)

Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
by: Frontiers Editorial Office
Published: (2025-01-01)

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
by: Sze-Ting Bong, et al.
Published: (2019-05-01)

Retraction: X-linked immunodeficient mice with no functional Bruton’s tyrosine kinase are protected from sepsis-induced multiple organ failure
by: Frontiers Editorial Office
Published: (2025-01-01)

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
by: Caroline A. Coughlin, et al.
Published: (2025-02-01)

Adverse Influence of Radio Frequency Background on Trembling Aspen Seedlings: Preliminary Observations
by: Katie Haggerty
Published: (2010-01-01)

Thermochemical Equilibrium Model of Synthetic Natural Gas Production from Coal Gasification Using Aspen Plus
by: Rolando Barrera, et al.
Published: (2014-01-01)

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia
by: Abhishek Abhishek, et al.
Published: (2023-09-01)

Experimental and Density Functional Theory Characteristics of Ibrutinib, a Bruton’s Kinase Inhibitor Approved for Leukemia Treatment
by: Ali I. Ismail
Published: (2021-01-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Mysterious Tasks of Tyrosines in Syndecan-1 Cytoplasmic Tail
by: Patricia Rousselle, et al.
Published: (2009-01-01)

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
by: Nikos G. Gavalas, et al.
Published: (2010-01-01)

l-Tyrosine and l-DOPA: Promising scaffolds for the synthesis of biologically active compounds
by: Ndayiragije, Euphrem, et al.
Published: (2024-11-01)

Effect of Microbial Community Succession on Tyrosine Metabolism during Soybean Paste Fermentation
by: JIN Manqin, LUO Dan, WANG Gangtu, LI Yixin, PEI Wei, XUE Wentong
Published: (2025-02-01)

Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise
by: Hassam Ali, et al.
Published: (2021-01-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

Development of a Multienzyme Cascade for Salvianolic Acid A Synthesis from l‑Tyrosine
by: Mingxi Zhang, et al.
Published: (2025-01-01)

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease
by: Thomas F Baumert, et al.
Published: (2025-01-01)

Identification of Flavonoid C-Glycosides as Promising Antidiabetics Targeting Protein Tyrosine Phosphatase 1B
by: Athika Rampadarath, et al.
Published: (2022-01-01)

Biotechnological melanin synthesized from tyrosine vs other precursors significantly affects its electrochemical response
by: J. Sayago, et al.
Published: (2025-01-01)

Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01)

Aseptic Splenic Abscess as Precursory Extraintestinal Manifestation of Inflammatory Bowel Disease
by: Joel Brooks, et al.
Published: (2014-01-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression
by: Elisa Carouge, et al.
Published: (2025-02-01)

Quenching-Chemiluminescence Determination of Trace Amounts of l-Tyrosine Contained in Dietary Supplement by Chemiluminescence Reaction of an Iron-Phthalocyanine Complex
by: Takao Ohtomo, et al.
Published: (2012-01-01)

The meaning of repeated assisted reproductive technologies failures experienced of older infertile women
by: Hyun Jung Oh, et al.
Published: (2025-02-01)

Tyrosine Kinase-2, Angiopoietin-2, and Thrombomodulin Axes in the Late-Onset Fetal Growth Restriction: A Prospective Cohort Study
by: Esra Altan Erbilen, et al.
Published: (2024-12-01)

Tyrosine supplementation is ineffective in facilitating soccer players' physical and cognitive performance during high-intensity intermittent exercise in hot conditions.
by: Kate J Donnan, et al.
Published: (2025-01-01)

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
by: Vineeth Sukrithan, et al.
Published: (2023-01-01)

Pharmacological Effects of JTT-551, a Novel Protein Tyrosine Phosphatase 1B Inhibitor, in Diet-Induced Obesity Mice
by: Makoto Ito, et al.
Published: (2014-01-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
by: T. D. de Gruijl, et al.
Published: (2007-01-01)

An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia
by: Mahmoud Fathy Hassan, et al.
Published: (2013-01-01)

Modulation of Tyrosine Hydroxylase, Neuropeptide Y, Glutamate, and Substance P in Ganglia and Brain Areas Involved in Cardiovascular Control after Chronic Exposure to Nicotine
by: Merari F. R. Ferrari, et al.
Published: (2011-01-01)